PSY-1, a Taxus chinensis var. mairei extract, inhibits cancer cell metastasis by interfering with MMPs

Natural Product Communications

Volumn 9, Issue 2, 2014, Pages 241-245

  Zheng, Zao Qian ^a   Fu, Ying Ying ^c   Li, Bo Heng ^c   Zhang, Mei Ling ^a   Yang, Xiu Li ^a   Xin, Chuan Wei ^a   Shi, Jia Na ^a   Ying, Yin ^a   Huang, Ping ^a,b  

^a TONGDE HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b Zhejiang Academy of Traditional Chinese Medicine   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Metastasis; MMPs; NF B; PSY 1

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; PLANT EXTRACT; POLYSACCHARIDE; PSY 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; METASTASIS; PLANT LEAF; TAXUS WALLICHIANA VAR. MAIREI; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; NEOPLASM METASTASIS; PLANT LEAVES; POLYSACCHARIDES; TAXUS;

EID: 84894415133     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x1400900228     Document Type: Article

References (43)

1. Chaffer CL, Weinberg RA. (2011) A perspective on cancer cell metastasis. Science, 331, 1559-1564.
2. Talmadge JE, Fidler IJ. (2010) AACR Centennial Series: The Biology of Cancer Metastasis: historical perspective. Cancer Research, 70, 5649-5669.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, ClarkePearson DL, Davidson M. (1996) Cyclophosphamide and cisplatin compared with Paclitaxel and Cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine, 334, 1-6. (Pubitemid 26012496)
4. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. (1991) Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. Journal of the National Cancer Institute, 83, 1797-1805.
5. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH, Hong WK. (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. Journal of the National Cancer Institute, 85, 384-388. (Pubitemid 23073156)
6. Forastiere AA. (1994) Current and future trials of Taxol (paclitaxel) in head and neck cancer. Annals of Oncology, 5 Suppl 6, S51-54.
7. Jones DV, Lozano R, Hoque A, Markowitz A, Patt YZ. (1996) Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. Journal of Clinical Oncology, 14, 2306-2310. (Pubitemid 26324154)
8. Rao S, Orr GA, Chaudhary AG, Kingston DGI, Horwitz SB. (1995) Characterization of the taxol binding site on the microtubule. 2-(m- azidobenzoyl) taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. Journal of Biological Chemistry, 270, 20235-20238.
9. Okano JI, Nagahara T, Matsumoto K, Murawaki Y. (2007) The growth inhibition of liver cancer cells by paclitaxel and the involvement of extracellular signal regulated kinase and apoptosis. Oncology Reports, 17, 1195-1200.
10. Rudner AD, Murray AW. (1996) The spindle assembly checkpoint. Current Opinion in Cell Biology, 8, 773-780. (Pubitemid 26399936)
11. Stein ME, Drumea K, AbuRasmi R, Haim N. (1997) Taxol-induced cellulitis after extravasation: a rarely reported event. American Journal of Clinical Oncology-Cancer Clinical Trials, 20, 540. (Pubitemid 27444358)
12. Herrington JD, Figueroa JA. (1997) Severe necrosis due to paclitaxel extravasation. Pharmacotherapy, 17, 163-165. (Pubitemid 27057130)
13. Hagiwara H, Sunada Y. (2004) Mechanism of taxane neurotoxicity. Breast Cancer, 11, 82-85.
14. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. (2007) Overview of resistance to systemic therapy in patients with breast cancer. Advances in Experimental Medicine and Biology, 608, 1-22.
15. Yin Y, Yu RM, Yang W, Yuan F, Yan CY, Song LY. (2010) Structural characterization and anti-tumor activity of a novel heteropolysaccharide isolated from Taxus yunnanensis. Carbohydrate Polymers, 82, 543-548.
16. Wu MB, Wu YL, Zhou J, Pan YJ. (2009) Structural characterization of a water-soluble polysaccharide with high branches from the leaves of Taxus chinensis var. mairei. Food Chemistry, 113, 1020-1024.
17. Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti-Passerini C. (2009) Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. International Journal of Cancer, 124, 1990-1996.
18. Eccles SA, Welch DR. (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet, 369, 1742-1757. (Pubitemid 46755391)
19. Chambers AF, Groom AC, MacDonald IC. (2002) Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2, 563-572. (Pubitemid 37328923)
20. Hanahan D, Weinberg RA. (2011) Hallmarks of cancer: The next generation. Cell, 144, 646-674.
21. Peinado H, Lavotshkin S, Lyden D. (2011) The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Seminars in Cancer Biology, 21, 139-146.
22. Talmadge JE, Fidler IJ. (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research, 70, 5649-5669.
23. Berx G, van Roy F. (2009) Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor Perspectives in Biology, 1, a003129.
24. Cavallaro U, Christofori G. (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nature Reviews Cancer, 4, 118-132. (Pubitemid 38198740)
25. Duffy MJ, McGowan PM, Gallagher WM. (2008) Cancer invasion and metastasis: changing views. Journal of Pathology, 214, 283-293. (Pubitemid 351212383)
26. Egeblad M, Werb Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2, 161-174. (Pubitemid 37328786)
27. Visse R, Nagase H. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circulation Research, 92, 827-839. (Pubitemid 36542523)
28. John A, Tuszynski G. (2001) The role of matrix metalloproteinases in tumour angiogenesis and tumor metastasis. Pathology & Oncology Research, 7, 14-23. (Pubitemid 32591662)
29. Szabo KA, Singh G. (2005) Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells. Breast Cancer Research, 7, 661-668.
30. Sellers A, Reynolds JJ, Meikle MC. (1978) Neutral metallo-proteinases of rabbit bone. Separation in latent forms of distinct enzymes that when activated degrade collagen, gelatin and proteoglycans. Biochemical Journal, 171, 493-496. (Pubitemid 8332729)
31. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. (2004) Expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 in breast cancer with a special reference to activator protein-2, Her2, and prognosis. Clinical Cancer Research, 10, 7621-7628. (Pubitemid 39557525)
32. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. (2004) A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clinical Cancer Research, 10, 1057-1063. (Pubitemid 38198907)
33. Bérubé M, Deschambeault A, Boucher M, Germain L, Petitclerc E, Guérin SL. (2005) MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Molecular Vision, 11, 1101-1111.
34. Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S, Ito A. (2004) Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecologic Oncology, 92, 47-56. (Pubitemid 38147370)
35. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostör AG, Nie G, Lopata A, Salamonsen LA. (2002) Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer, 94, 1466-1475. (Pubitemid 34213290)
36. Huang SY, DeGuzman A, Bucana CD, Fidler IJ. (2000) Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cellular and Molecular Therapy, 6, 9-17. (Pubitemid 30664319)
37. Huang SY, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene, 20, 4188-4197. (Pubitemid 32762193)
38. Baby J, Pickering BF, Gopal YNV, Van Dyke MW. (2007) Constitutive and inducible nuclear factor-kappaB in immortalized normal human bronchial epithelial and non-small cell lung cancer cell lines. Cancer Letters, 255, 85-94. (Pubitemid 47212609)
39. Shishodia S, Aggarwal BB. (2002) Nuclear factor-kappaB activation: a question of life or death. Journal of Biochemistry and Molecular Biology, 35, 28-40.
40. Sethi G, Sung B, Aggarwal BB. (2008) Nuclear factor-κB activation: From bench to bedside. Experimental Biology and Medicine, 233, 21-31.
41. Bond M, Fabunmi RP, Baker AH, Newby AC. (1998) Synergistic up-regulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Letters, 435, 29-34. (Pubitemid 28432009)
42. Kim Y, Kang H, Jang SW, Ko J. (2011) Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression. Cellular Physiology and Biochemistry, 28, 175-184.
43. Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, Tanaka M, Katano M. (2004) Increased nuclear factor-kappa B activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Research, 24, 675-681. (Pubitemid 38625006)